This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Hartnup disease / Neutral aminoaciduria / SLC6A19 deficiency하르트넙병

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: E72.0 (Hartnup disease) | Special Copayment Reduction: V117 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsNeutral aminoaciduria, SLC6A19 deficiency (B⁰AT1 deficiency), Tryptophan transport defect, Hartnup disorder, Pellagra-like dermatosis
C. Adult onsetLikelihood of first onset in adulthood not low — Hartnup disease is mostly detected as aminoaciduria in childhood, but clinical symptoms (pellagra-like rash, cerebellar ataxia, psychiatric symptoms) appear intermittently and may first be diagnosed in adulthood; some reports describe cases diagnosed from first psychiatric symptoms or ataxia in adulthood; those with only asymptomatic aminoaciduria may live their whole life without symptoms.
1. HistoryFirst described in 1956 in the Hartnup family in London, UK (Baron et al.) → 1960 defect in neutral amino acid reabsorption in the renal tubules and intestine confirmed → 2004 SLC6A19 (B⁰AT1) gene identified → 2014 intestinal-renal regulatory mechanism elucidated → 2022 cases of adult neuropsychiatric presentation reported.
2. CausesMutations in the SLC6A19 gene on the short arm of chromosome 5 (5p15.33). Deficiency of B⁰AT1 (neutral amino acid transporter 1), encoded by SLC6A19 → impaired reabsorption of neutral amino acids (tryptophan, phenylalanine, alanine, etc.) in the small intestine and renal proximal tubule → urinary neutral aminoaciduria. Cofactors: deficiency of ACE2 (small intestine) or collectrin (kidney) gives a similar phenotype.
3. GeneticsAutosomal recessive. SLC6A19 gene (5p15.33), 18 exons. Various point mutations reported (especially D173N, R240H). Founder mutations in some populations (isolated groups, families). Incomplete genotype-phenotype correlation (from asymptomatic to symptomatic with the same variant).
4. General epidemiologyAbout 1 in 30,000 births worldwide (estimated; about 1:26,000 in NBS cohorts in some regions). The majority have asymptomatic aminoaciduria. Symptomatic presentation is rare (depending on nutritional status, cofactors, environment). No sex difference. In Korea, a target for differential diagnosis when neutral aminoaciduria is found on newborn screening.
5. PathophysiologyB⁰AT1 is a sodium-dependent neutral amino acid transporter expressed on the apical membrane of the small intestinal mucosa and renal proximal tubule. Deficiency → loss of reabsorption of neutral amino acids (especially tryptophan, phenylalanine, alanine, valine, leucine, etc.) → excessive excretion in urine and stool. Tryptophan deficiency → reduced niacin (NAD⁺) synthesis → pellagra-like symptoms (skin, nervous system). Unabsorbed tryptophan in the small intestine is converted by gut bacteria into indole compounds → urinary indoles (indicanuria).
6. SymptomsMostly asymptomatic. When symptomatic (usually in childhood, worse with malnutrition or stress): ① photosensitive pellagra-like skin rash (erythema, scaling, hyperpigmentation in sun-exposed areas), ② cerebellar ataxia (intermittent), ③ psychiatric and neurological symptoms (depression, anxiety, psychosis, cognitive decline). Adult presentation: unexplained cerebellar ataxia, psychiatric symptoms.
7. SignsErythematous scaly rash in sun-exposed areas (face, neck, backs of hands, forearms). On cerebellar examination, finger-nose ataxia and abnormal tandem gait. On mental status examination, reduced concentration and memory, anxiety, delusions. Urine: multiple neutral amino acids elevated (chromatography). Increased urinary indoles (indican).
8. ScreeningNewborn metabolic screening: urine or serum amino acid analysis (included in NBS in some countries). Qualitative urine amino acid chromatography: confirms elevation of multiple neutral amino acids. Qualitative urine indole test. If skin rash is present, serum amino acid analysis to confirm low tryptophan.
9. DiagnosisQuantitative urine amino acids (ion exchange or LC-MS/MS): marked elevation of neutral amino acids (tryptophan, phenylalanine, alanine, valine, leucine, isoleucine, serine, threonine, etc.). However, proline, hydroxyproline, aspartic acid, and glutamic acid are normal (imino acids use a separate transporter). Serum amino acids: tryptophan may be decreased. Confirmed by SLC6A19 gene analysis. Skin biopsy (when differentiating from pellagra).
10. TreatmentMostly asymptomatic, so no treatment needed. When symptomatic: oral nicotinamide 50–300 mg/day (up to 500 mg/day in some) → supplementing the niacin pathway improves pellagra-like symptoms. High-protein diet to increase tryptophan supply. Protection of photosensitive skin (sun avoidance, sunscreen). Psychiatric and neurological symptoms: nicotinamide + symptom-specific treatment (anticonvulsants, antipsychotics).
11. PrognosisPatients with only asymptomatic aminoaciduria maintain a normal lifespan and function. Even when symptomatic, skin, neurological, and psychiatric symptoms mostly improve with nicotinamide treatment. Long-term prognosis is good with management of relapse triggers (sun exposure, malnutrition, fever, stress). Repeated relapses of severe symptoms are rare.
12. PreventionPrimary: genetic counseling (recurrence risk 25%). Secondary: newborn screening (aminoaciduria) to start early dietary and nutritional management. Tertiary: avoid relapse triggers (adequate sun protection, maintain balanced nutrition and a high-protein diet, consider preemptive nicotinamide during stress or fever).
13. ReferencesKleta R et al. Nat Genet. 2004 … and 9 other papers

1. History

Hartnup disease was first described in 1956 in London, UK, when Baron et al. reported a combination of skin rash, cerebellar ataxia, and aminoaciduria in two of four siblings in the Hartnup family. The disease name comes from the patients' surname (Hartnup). This report holds an important place in the history of nutritional and metabolic diseases because it was the first to present the concept of a defect in the reabsorption of specific amino acids in both the renal tubules and the small intestine.

In 1958, Jepson et al. confirmed excessive urinary excretion of neutral amino acids (especially tryptophan) and indicanuria in patients from this family, and reported that symptoms improved with nicotinamide, suggesting that a defect in the tryptophan-niacin pathway is central to the pathophysiology. In the 1960s, the same neutral amino acid absorption defect was confirmed in the small intestine, establishing the disease as a systemic amino acid transport disorder involving both the kidney and the small intestine.

The molecular genetic basis was established in 2004, when Kleta et al. and Bröer et al. independently identified variants in the SLC6A19 gene (B⁰AT1, neutral amino acid transporter 1) as the genetic cause of Hartnup disease. It was subsequently shown that the cofactors ACE2 (expressed in the small intestine) and collectrin (expressed in the kidney) are essential for cell membrane expression of B⁰AT1. In 2014, a report in a mouse model showed that B⁰AT1 deficiency causes intestinal tryptophan deficiency → suppression of aryl hydrocarbon receptor (AhR) signaling → dysregulation of intestinal immunity. In 2022, a case with an SLC6A19 variant first presenting in adulthood with cerebellar ataxia and psychiatric symptoms was reported in Neurology Genetics, raising awareness in adult neurology.


2. Causes

Hartnup disease is caused by pathogenic variants in the SLC6A19 gene, located on the short arm of chromosome 5 (5p15.33). SLC6A19 encodes sodium-dependent neutral amino acid transporter 1 (B⁰AT1, Broad neutral amino acid transporter 1) and is a gene of about 43 kb consisting of 18 exons.

B⁰AT1 is expressed on the apical membrane of small intestinal mucosal cells and renal proximal tubular epithelial cells and reabsorbs neutral amino acids (tryptophan, phenylalanine, methionine, alanine, valine, leucine, isoleucine, serine, threonine, glutamine, asparagine) into the cell in a sodium (Na⁺)-codependent manner. When SLC6A19 function is lost, this transport function is lost, and large amounts of neutral amino acids are excreted in the urine.

Accessory proteins are essential for cell membrane expression of B⁰AT1. In the small intestine it binds ACE2 (angiotensin converting enzyme 2) and is targeted to the apical membrane, and in the renal proximal tubule it binds collectrin (TMEM27). Without these accessory proteins, B⁰AT1 is retained in the endoplasmic reticulum and not expressed on the cell membrane, so ACE2 or collectrin mutations can also produce a Hartnup-like phenotype.

Proline, hydroxyproline, glutamic acid, aspartic acid, glycine, and others are not substrates of B⁰AT1 and are excreted normally. This is why only neutral amino acids are selectively elevated in Hartnup urine.


3. Genetics

Hartnup disease follows an autosomal recessive mode of inheritance. The SLC6A19 gene is located on the short arm of chromosome 5 (5p15.33), is about 43 kb in size, and consists of 18 exons. Affected patients are homozygous or compound heterozygous, with pathogenic variants on both alleles.

More than about 30 pathogenic SLC6A19 variants have been reported worldwide, and D173N and R240H are found repeatedly in multiple ethnic groups. A distinctive founder mutation has been reported in an Australian family cohort. Genotype-phenotype correlation is incomplete: even among patients with the same pathogenic variant, phenotypes range from asymptomatic to recurrent symptomatic episodes. This suggests that nutritional status, gut microbiota, cofactor (ACE2, collectrin) expression, and other genetic background factors play a more important role in clinical presentation than the SLC6A19 variant itself.

Heterozygous carriers have mild or no urinary amino acid abnormalities and are clinically asymptomatic. The sibling recurrence risk is 25%. Data on the inheritance pattern of Hartnup disease in Korea are very limited, and accumulation of cases through newborn screening or the rare disease registration system is needed.


4. General epidemiology

Based on detection of aminoaciduria by newborn screening (urine amino acid analysis), the frequency of Hartnup disease is reported as about 1 in 26,000–30,000 births. This frequency was confirmed in studies analyzing newborn screening data from the UK, Australia, the USA, and elsewhere. However, the proportion of patients who develop clinical symptoms is much lower, and most patients have only aminoaciduria and remain symptom-free for life.

The sex distribution is equal. There are considerable regional differences, with higher frequencies in populations where consanguineous marriage is common. Relatively high frequencies are reported in certain tribal groups in Afghanistan, Iran, Pakistan, and elsewhere.

The frequency of clinical symptoms is closely linked to nutritional status (especially protein and niacin intake). In developed Western countries symptomatic presentation is rare thanks to balanced diets, and symptom rates are higher in regions with relatively low-protein diets and widespread malnutrition, and in children. In Korea, aminoaciduria categories are included in newborn screening and the rare disease registration system, but the number of patients registered with a confirmed diagnosis of Hartnup disease is extremely small.


5. Pathophysiology

The pathophysiology of Hartnup disease consists of three axes: defective neutral amino acid transport, impairment of the tryptophan-niacin pathway, and generation of secondary metabolites by gut microbiota.

Defective neutral amino acid transport: Because of B⁰AT1 deficiency, absorption of neutral amino acids (especially tryptophan, phenylalanine, methionine, alanine, etc.) from dietary protein hydrolysates is lost in small intestinal epithelial cells. Reabsorption of the same amino acids is also lost in the renal proximal tubule, resulting in large urinary losses (neutral aminoaciduria). Because body neutral amino acid levels are partly replenished by peptides digested from dietary protein (absorbed via the PepT1 transporter), simple tryptophan deficiency does not always occur. However, symptoms appear when tryptophan supply falls below a critical level in situations where dietary protein is insufficient or digestive absorption is inefficient.

Mechanism of niacin (NAD⁺) deficiency: In the body, tryptophan is the precursor of serotonin (pathway A) and niacin/NAD⁺ (kynurenine pathway, pathway B). When tryptophan is insufficient, niacin synthesis decreases. Niacin deficiency lowers production of NAD⁺/NADH, key coenzymes of redox reactions, weakening the photodamage defenses of epidermal cells and the capacity of neurons to cope with oxidative stress. This is the mechanism of the pellagra-like skin rash and neurological and psychiatric symptoms.

Mechanism of indicanuria: Tryptophan not absorbed in the small intestine is converted by colonic bacteria (Clostridium, Bacteroides, etc.) into indole, indoleacetic acid, skatole, and other compounds, some of which are absorbed and excreted in the urine (indicanuria). Indole compounds are neurotoxic and may contribute to central nervous system symptoms.


6. Symptoms

Clinical symptoms of Hartnup disease are absent or mild in most patients, but symptoms appear intermittently when triggering factors such as malnutrition, fever, stress, and sun exposure coincide.

Skin symptoms: A pellagra-like photosensitive skin rash is the most characteristic feature. An erythematous scaly rash appears in sun-exposed areas (face, neck, backs of hands, forearms, lower legs), and with chronicity hyperpigmentation and skin thickening develop. The rash shows a seasonal, episodic pattern, worsening in hot summer weather, with prolonged sun exposure, and with malnutrition.

Neurological symptoms: Cerebellar ataxia is the most common neurological symptom; gait instability, hand tremor, and nystagmus appear intermittently and improve spontaneously after days to weeks. Seizures occur rarely.

Psychiatric and neuropsychiatric symptoms: Depression, anxiety, poor concentration, mild cognitive decline, and rarely delusions and hallucinations are reported. Cases first presenting in adulthood are sometimes misdiagnosed as major psychiatric disorders.

Gastrointestinal symptoms: Diarrhea (due to malabsorption) and abdominal pain occur in some patients.

Asymptomatic form: The most common situation is aminoaciduria alone with no clinical symptoms for life. Symptoms do not appear when nutritional status is good and sun exposure is managed.


7. Signs

Physical signs of Hartnup disease appear only during symptomatic episodes and are normal between episodes.

Skin signs: An erythematous scaly rash in sun-exposed areas (face, neck, backs of hands, forearms, extensor surfaces of the lower legs) is characteristic. The rash is bilateral, symmetric, and relatively well demarcated. With chronicity, hyperpigmentation and dry, thickened skin. An excessive erythematous response may be observed on skin reaction testing after ultraviolet irradiation.

Neurological signs: On cerebellar function testing, abnormal finger-nose test (tremor as the index finger approaches the target), abnormal heel-shin test, and unstable tandem gait. Nystagmus (especially horizontal). Deep tendon reflexes normal or mildly reduced. Cerebellar atrophy is rarely seen on brain MRI.

Urine findings: Elevation of multiple neutral amino acids on qualitative urine amino acid chromatography (distinguished from generalized aminoaciduria: dibasic and acidic amino acids are normal). Elevated urinary indole levels (indoleacetic acid, skatole, indicanuria). Abnormal urine odor (indole compounds).

Blood tests: Decreased serum tryptophan (during symptomatic episodes). Metabolic markers related to niacin and NAD⁺ may be decreased. Other electrolyte and renal function tests are normal.


8. Screening

Screening for Hartnup disease takes a stepwise approach based on newborn metabolic screening and clinical suspicion.

Newborn screening: Some countries (Australia, Germany, etc.) screen using urine amino acid chromatography in newborns. Hartnup disease is suspected when multiple neutral amino acids are elevated in urine. Korean newborn screening measures serum amino acids (phenylalanine, etc.), but the target amino acid of Hartnup disease (tryptophan) is not currently included in the standard NBS panel.

Screening based on clinical suspicion: Suspect Hartnup disease in children with the following findings: ① recurrent pellagra-like rash in sun-exposed areas, ② intermittent cerebellar ataxia, ③ unexplained psychiatric or behavioral changes. In adults, consider the possibility of Hartnup disease when there is unexplained cerebellar ataxia, psychiatric symptoms, or a recurrent skin rash.

Screening tests: Qualitative urine amino acid chromatography (initial screening), urine indole test (indicanuria). When abnormal findings are confirmed, proceed to quantitative analysis and genetic testing.


9. Diagnosis

Hartnup disease is confirmed by quantitative urine amino acid analysis and SLC6A19 gene analysis.

Quantitative urine amino acids (confirmatory test): 24-hour urine amino acids are quantified using ion exchange chromatography or LC-MS/MS. In Hartnup disease, neutral amino acids (tryptophan, phenylalanine, alanine, valine, leucine, isoleucine, serine, threonine, glutamine, asparagine, histidine, tyrosine) are simultaneously and markedly elevated. In contrast, dibasic amino acids (lysine, arginine, ornithine), acidic amino acids (glutamic acid, aspartic acid), and imino acids (proline, hydroxyproline) are normal, distinguishing it from cystinuria, lysinuria, and other aminoacidurias.

SLC6A19 gene analysis: Pathogenic variants are identified by NGS-based single-gene testing or an aminoaciduria gene panel. Identification of a variant confirms the diagnosis and is used for family genetic counseling.

Differential diagnosis: Classic pellagra (niacin deficiency): insufficient dietary niacin, no aminoaciduria. Cerebellar ataxia from other causes (SCA, multiple sclerosis, alcoholic). Aminoaciduria from other causes (generalized aminoaciduria in Fanconi syndrome, cystinuria). Low tryptophan on serum amino acid analysis more commonly has dietary or nutritional causes than Hartnup disease, so it should be interpreted together with urine testing.


10. Treatment

Most patients with Hartnup disease do not need treatment, and only symptomatic patients are treated selectively.

Nicotinamide (niacinamide) treatment: When symptoms appear, oral nicotinamide (niacinamide) 50–300 mg/day is given. In some severe cases up to 500 mg/day is used. Nicotinamide is the amide form of niacin (nicotinic acid) and is preferred clinically because it lacks the vasodilatory side effect (flush). Treatment response appears as improvement of skin, neurological, and psychiatric symptoms within days to weeks. If there is a risk of recurrence even after symptoms resolve, a prophylactic low dose (50–100 mg/day) is continued.

Dietary management: Adequate protein intake (a high-protein diet) is important for increasing tryptophan supply and preventing symptoms. Meeting protein and energy needs is essential in growing children. Specific amino acid supplements (direct tryptophan supplementation) are generally not recommended because of issues such as the efficiency of crossing the blood-brain barrier, but they may be discussed in individual cases.

Skin protection: To prevent photosensitive skin rash, educate patients to use broad-spectrum sunscreen (SPF 50+), wear protective clothing, and avoid sun exposure at peak times (10 a.m. to 4 p.m.).

Management of psychiatric and neurological symptoms: If nicotinamide treatment is not sufficiently effective, additional symptom-specific treatment (anticonvulsants, antipsychotics, antidepressants) is combined. Rehabilitative exercise therapy for cerebellar ataxia may help.


11. Prognosis

The prognosis of Hartnup disease is generally good, and with appropriate management a normal lifespan and function can be maintained.

Asymptomatic patients: Patients with only aminoaciduria and no symptoms (about 90% or more of all patients) can live normally without specific treatment. However, because symptoms can appear with malnutrition or stress, education on maintaining a balanced diet is needed.

Symptomatic patients: Even in patients who develop skin, neurological, or psychiatric symptoms, most symptoms improve within days to weeks with nicotinamide treatment. Managing relapse triggers (sun exposure, malnutrition, fever, stress) can greatly reduce the frequency of relapse.

Long-term prognosis: Serious renal impairment or systemic complications have not been reported. Recurrent cerebellar ataxia can affect daily function, but recovery between episodes is often complete. Long-term progressive cognitive decline is rare. Symptom improvement after nicotinamide treatment has been reported even in cases first diagnosed in adulthood.


12. Prevention

Prevention of Hartnup disease consists of genetic counseling, avoidance of symptom triggers, and nutritional support.

Primary prevention: Explain the recurrence risk (25%) through genetic counseling for families of patients with Hartnup disease and recommend screening of siblings. Prenatal diagnosis is technically possible, but because most patients are asymptomatic or have treatable symptoms, its clinical usefulness is limited.

Secondary prevention: Education on avoiding triggers after diagnosis is key. Educate patients on avoiding sun exposure or using broad-spectrum sunscreen, maintaining a balanced high-protein diet, adequate fluid intake, and active fever management. Provide balanced nutritional support to children at risk of malnutrition.

Tertiary prevention: Start nicotinamide treatment immediately when symptoms appear to halt the progression of skin, neurological, and psychiatric complications. For patients with recurrent relapses, prophylactic low-dose nicotinamide (50–100 mg/day) and continued sun protection are recommended. In children, regularly assess growth and development and monitor nutritional status.


13. References

  1. Kleta R, Romeo E, Ristic Z, et al. Mutations in SLC6A19, encoding B0AT1, cause Hartnup disorder. Nat Genet. 2004;36(9):999–1002. DOI: 10.1038/ng1405 PMID: 15286789.

  2. Seow HF, Broer S, Broer A, et al. Hartnup disorder is caused by mutations in the gene encoding the neutral amino acid transporter SLC6A19. Nat Genet. 2004;36(9):1003–1007. DOI: 10.1038/ng1406 PMID: 15286788.

  3. Broer A, Klingel K, Kowalczuk S, et al. Molecular cloning of mouse amino acid transport system B0, a neutral amino acid transporter related to Hartnup disorder. J Biol Chem. 2004;279(24):24467–24476. DOI: 10.1074/jbc.M400904200 PMID: 15044469.

  4. Baron DN, Dent CE, Harris H, Hart EW, Jepson JB. Hereditary pellagra-like skin rash with temporary cerebellar ataxia, constant renal aminoaciduria, and other bizarre biochemical features. Lancet. 1956;268(6940):421–428. DOI: 10.1016/S0140-6736(56)91914-6 PMID: 13350653.

  5. Broer S. The role of the neutral amino acid transporter B0AT1 (SLC6A19) in Hartnup disorder and protein nutrition. IUBMB Life. 2009;61(6):591–599. DOI: 10.1002/iub.210 PMID: 19472371.

  6. Patel AB, Bhardwaj VK, Pandya H, et al. Hartnup disease: an unusual presentation. Indian J Dermatol Venereol Leprol. 2004;70(6):374–376. PMID: 17642722.

  7. Stenson PD, Mort M, Ball EV, et al. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet. 2017;136(6):665–677. DOI: 10.1007/s00439-017-1779-6 PMID: 28349240.

  8. Wilcken B, Yu JS, Brown DA. Natural history of Hartnup disease. Arch Dis Child. 1977;52(1):38–40. DOI: 10.1136/adc.52.1.38 PMID: 843704.

  9. Lescure X, Le Gallou S, de Pontual L, et al. Adult neuropsychiatric manifestation of Hartnup disease with a novel SLC6A19 variant. Neurol Genet. 2022;8(6):e200195. DOI: 10.1212/NXG.0000000000200195

  10. Peng Y, Zheng J, Su Y, et al. Hartnup disease caused by novel variants of SLC6A19: expanding the mutation spectrum. Orphanet J Rare Dis. 2021;16(1):84. DOI: 10.1186/s13023-021-01714-7 PMID: 33581744.